CORMEDIX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.38 USD | -7.88% |
|
+13.03% | +43.09% |
| Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
| Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.38
USD
Average target price
13
USD
Spread / Average Target
+141.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.09% | 296M | |
| +11.88% | 9.26B | |
| -16.73% | 4.72B | |
| +23.84% | 3.89B | |
| +1.45% | 3.75B | |
| +32.57% | 2.66B | |
| -24.17% | 2.37B | |
| -27.04% | 2.17B | |
| +3.63% | 1.64B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- Earnings Flash (CRMD) CORMEDIX Posts Q2 Revenue $21,253
